key: cord-0978426-mci94kro
authors: Haberman, Rebecca H; Herati, Ramin; Simon, David; Samanovic, Marie; Blank, Rebecca B; Tuen, Michael; Koralov, Sergei B; Atreya, Raja; Tascilar, Koray; Allen, Joseph R; Castillo, Rochelle; Cornelius, Amber R; Rackoff, Paula; Solomon, Gary; Adhikari, Samrachana; Azar, Natalie; Rosenthal, Pamela; Izmirly, Peter; Samuels, Jonathan; Golden, Brian; Reddy, Soumya M; Neurath, Markus F; Abramson, Steven B; Schett, Georg; Mulligan, Mark J; Scher, Jose U
title: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
date: 2021-06-07
journal: Ann Rheum Dis
DOI: 10.1136/annrheumdis-2021-220597
sha: 8bdaf2d396445eb4ef326ec68ed2b2c3019ea2ec
doc_id: 978426
cord_uid: mci94kro

OBJECTIVE: To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. METHODS: Established patients at New York University Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunisation. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analysed for humoral response. Cellular immune response to SARS-CoV-2 was further analysed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany, were also analysed for humoral immune response. RESULTS: Although healthy subjects (n=208) and patients with IMID on biologic treatments (mostly on tumour necrosis factor blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, patients with IMID on methotrexate do not demonstrate an increase in CD8+ T-cell activation after vaccination. CONCLUSIONS: In two independent cohorts of patients with IMID, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut-offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunisation efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines.

Patients with immune-mediated inflammatory diseases (IMIDs) have an inherently heightened susceptibility to infection and may thus be considered high risk for developing COVID-19. Importantly, however, the strength of response to viral vaccines (ie, influenza and hepatitis B) and their long-lasting protective effects in patients with IMID taking conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, or biologic DMARDs, such as tumour necrosis factor inhibitors (TNFis), may not be as robust

What is already known about this subject? ► The impact of COVID-19 has been felt across the globe, and new hope has arisen with the approval of messenger RNA (mRNA) vaccines against SARS-CoV-2. Studies have shown immunogenicity and efficacy rates of over 90% in the immunocompetent adult population. However, there is a lack of knowledge surrounding the response of patients with immune-mediated inflammatory diseases (IMIDs) who may also be on immunomodulatory medications. ► Patients with IMID have been shown to have attenuated immune responses to seasonal influenza vaccination.

What does this study add? ► This study looks at the humoral and cellular immune response to two doses of BNT162b2 mRNA COVID-19 vaccine in participants with IMID (on immunomodulators) compared with healthy controls. ► Individuals with IMID on methotrexate demonstrate up to a 62% reduced rate of adequate immunogenicity to BNT162b2 mRNA vaccination. Those on anticytokine or nonmethotrexate oral medications demonstrate similar levels of immunogenicity as healthy controls (greater than 90%). ► Similarly, vaccination did not induce an activated CD8+ T-cell response in participants on background methotrexate, unlike healthy controls and patients with IMID not receiving methotrexate.

as it is in the general population following immunisation. [1] [2] [3] [4] [5] Data regarding messenger RNA (mRNA) COVID-19 vaccines' safety, immunogenicity and efficacy are rapidly emerging for the immunocompetent adult population, 6 where more than 90% of subjects achieve a satisfactory humoral response. However, the ability of patients with IMID to adequately respond to these vaccines and the differences in humoral and cellular immune response to SARS-CoV-2 vaccination are not known, leaving a significant gap in knowledge that prevents optimal management of this patient population. Given the experience with seasonal influenza vaccine immunogenicity, 2 7 we hypothesised that patients with IMID treated chronically with certain conventional synthetic DMARDs (ie, methotrexate) would have an attenuated response to mRNA COVID-19 vaccines compared with patients with IMID receiving anticytokine treatment or non-IMID participants. To achieve this, we obtained preimmunisation and postimmunisation peripheral blood monocyte cells (PBMCs) and sera from IMID participants (n=82) in two independent cohorts (SAGA (Serologic Testing and Genomic Analysis of Autoimmune, Immune-Mediated and Rheumatic Patients with COVID-19) cohort in New York City, USA, and Erlangen, Germany) and analysed SARS-CoV-2 spike-specific antibody titres compared with non-IMID controls (n=208). Cellular immune responses were further investigated using high-dimensional spectral flow cytometry in the New York City cohort.

Established patients with IMID (n=51) receiving methotrexate, anticytokine biologics or both participating in the SAGA study at New York University Langone Health in New York City, 8 who were receiving BNT162b2 mRNA vaccination were assessed at baseline and after the second dose during the period from 23 December 2020 through 31 March 2021. Healthy subjects served as controls (n=26). IgG antibody responses to the S protein were analysed for humoral immune response. A second independent validation cohort of controls (n=182) and patients with IMID (n=31) on either TNFi or methotrexate monotherapy from Erlangen, Germany, was also analysed for humoral response. Cellular immune responses to the vaccine were also studied for the New York SAGA participants using high-parameter spectral flow cytometry.

Humoral immune response was assessed by testing IgG antibodies against the spike protein of SARS-CoV-2. 9 In the New York City cohort, direct ELISA was used to quantify antibody titres on serum as previously described. 10 Titre of 5000 units or greater was used as the cut-off to determine an adequate response to vaccination. IgG antibodies against the S1 domain of the spike protein of SARS-CoV-2 were tested in Erlangen participants using the commercial ELISA from Euroimmun (Lübeck, Germany) on the EUROIMMUN Analyzer I platform and according to the manufacturer's protocol. 11 Adequate response was defined as greater than 5.7 nm OD. Immune cell phenotyping before and after immunisation in New York participants was performed by 35-colour spectral flow cytometry on PBMCs. Further details on methodology and analysis can be found in the online supplemental appendix.

Patient characteristics were summarised using means, medians, SD, ranges and percentages as appropriate. χ 2 tests of independence and Fisher's exact tests were used for categorical data. Mann-Whitney U and Kruskal-Wallis tests were used for unpaired continuous data, and Wilcoxon signed-rank tests were used for paired continuous data. A p value of less than 0.05 was considered significant. All analyses were done using R V.3.6.0 software (R Foundation for Statistical Computing) and GraphPad Prism V.9 (GraphPad Software).

This study was designed in response to frequent questions asked by patients with IMID but did not contain any direct public involvement.

The New York City cohort comprised 26 healthy individuals, 25 individuals with IMID receiving methotrexate monotherapy or in combination with other immunomodulatory medications, and 26 individuals with IMID on anticytokine therapy and/or other oral immunomodulators (table 1) . Healthy individuals and those with IMID not on methotrexate were similar in age (49.2±11.9 years and 49.1±14.9 years, respectively), whereas patients with IMID receiving methotrexate were generally older (63.2±11.9 years). IMID diagnoses were predominantly psoriasis/psoriatic arthritis and rheumatoid arthritis. The Erlangen cohort consisted of 182 healthy subjects, 11 subjects with IMID receiving TNFi monotherapy and 20 subjects with IMID on methotrexate monotherapy (online supplemental table 1). Individuals on methotrexate monotherapy were on average older than healthy individuals and those with IMID not on methotrexate (54.5±19.2 vs 40.8±12.0 and 45.0±15.5, respectively). figure S1 ). Because of the imbalance in age between groups, we further analysed immunogenicity based on a cut-off age of 55. In both Epidemiology age groups, the response rate for those on methotrexate remained significantly lower (p<0.001) (online supplemental figure S2 ).

As an added sensitivity analysis, we used a stricter definition of inadequate antibody response (ie, less than 1000 units for New York City cohort and less than 5 OD for the Erlangen cohort).

With the use of these more conservative cut-off levels, patients with IMID on background methotrexate continued to show significantly decreased antibody response (p<0.001) (online supplemental figure S3 ).

In the New York City cohort, 20 healthy controls, 24 patients with IMID not receiving methotrexate and 18 patients with IMID who were receiving methotrexate underwent immune cell phenotyping before and after vaccination. The proportions of spike-specific B cells, circulating T follicular helper (cTfh; CD4+ ICOS+ CD38+ subset) cells, activated CD4+ T cells and HLA-DR+ CD8+ T cells increased significantly in all groups after immunisation ( figure 2A-D) . Activated CD8+ T cells, defined as CD8+ T cells expressing Ki67 and CD38, and the granzyme B-producing (GZMB) subset of these activated CD8+ T cells were induced in healthy adults and participants with IMID not on methotrexate, but not induced in patients receiving methotrexate ( figure 2E,F) .

In two geographically independent cohorts of patients with IMID, we found that methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immunogenicity to COVID-19 mRNA vaccines.

For humoral immunity, the BNT162b2 mRNA vaccines did not induce adequately elevated SARS-CoV-2 spike-specific IgG antibody titres in up to a third of the patients on methotrexate, compared with patients with IMID on other DMARDs, who demonstrated a response as robust as that of healthy controls. This finding was analogous to the previously described effects of methotrexate on influenza vaccine immunogenicity. 5 12-14 While a recent report has shown no differences in immunogenicity for patients with IMID, none of the included participants were on methotrexate. 15 A second study in patients with selfreported rheumatic and musculoskeletal diseases recruited via social media showed that 10 of 13 participants on background methotrexate had detectable antibody levels after only one dose of SARS-CoV-2 mRNA vaccine, 16 although this was both underpowered and used a semiquantitative ELISA measuring antibodies against SARS-CoV-2 receptor-binding domain. Therefore, the findings from our work looking at antibody responses in patients with IMID after full vaccination regimen are of potentially high clinical relevance because it was recently shown that a temporary discontinuation of methotrexate for 2 weeks significantly improved influenza vaccine immunogenicity in patients with rheumatoid arthritis. 2 Importantly, the use of high-dimensional spectral flow cytometry allowed for the interrogation of specific cellular immune responses before and after immunisation. Spike-specific B cells, activated CD4+ T cells and cTfh cells were induced similarly in all groups after mRNA vaccination. In contrast, activated CD8+ T-cell responses were notably attenuated in the methotrexate cohort. Moreover, the poor induction of activated CD8+ T cells expressing granzyme B may indicate reduced cytotoxic functionality of these cells. Indeed, CD8+ T-cell responses were identified to be a correlate of protection in non-human primate studies of SARS-CoV-2 infection. 17 Thus, reduced induction of cytotoxic CD8+ T-cell responses, combined with inconsistent induction of antibody responses, may further impair the effectiveness of COVID-19 vaccines and render patients with IMID on methotrexate more at risk of inadequate vaccine response. However, this finding requires a cautious interpretation as it is quite possible that the use of methotrexate may delay (rather than prevent) adequate cellular mediated immunity against SARS-CoV-2. While spike-specific T-cell immunity has been detected as early as 10 days following one dose of mRNA COVID-19 vaccines in healthy individuals, 18 mRNA-1273-specific CD4+ and CD8+ T-cell responses were most robustly elicited 2 weeks after the second dose. 19 Therefore, more detailed and comprehensive studies that include long-term characterisation of the dynamics of cellular responses to these vaccines will be required to understand the clinical implications of these findings.

Although our analysis was limited in sample size, followed participants with biosampling for a relatively short period of time without standardised disease activity status metrics and was restricted to one type of mRNA immunisation, our findings were validated in an independent cohort and revealed that methotrexate, which is widely used for many indications, adversely affected the humoral and cellular immunogenicity to COVID-19 mRNA vaccination. Furthermore, because of the inclusion of patients with prior COVID-19 infection, it is possible that results could be biased in favour of those not on methotrexate. However, when excluding all patients with prior infection, the results remained similar. We also acknowledge that there may have been participants with asymptomatic COVID-19 infection that we have not captured. While immunosenescence may reduce the level of antibody responses to immunisations, 20 recent studies on COVID-19 mRNA vaccines have not shown differences in clinical outcomes for the older population. 6 In our study, patients with IMID on methotrexate were generally older, which may potentially explain some differences in immunogenicity. However, even when looking at participants younger than 55 years, decreased rates of humoral response were still significant. Further validation in even larger cohorts that address efficacy will be required to understand the interaction between age and methotrexate in the context of COVID-19 vaccination.

Importantly, it is not yet clear what level of immunogenicity is representative of vaccine efficacy (and this includes the arbitrary cut-offs chosen for our measurements). We recognise that the definition of adequate cellular and humoral immune response may need to be refined in the future when correlation with efficacy becomes available. However, even after applying more conservative cut-offs, the hampering effects of methotrexate on immunogenicity are still evident.

Taken together, our results suggest that the optimal protection of patients with IMID against COVID-19 will require further studies to determine whether additional doses of vaccine, dose modification of methotrexate or even temporary discontinuation of this drug can boost immune response as has been demonstrated for other viral vaccines in this patient population. 7 

Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease

Tnf blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Covid-19 in immune-mediated inflammatory diseases -case series from New York

A serological assay to detect SARS-CoV-2 seroconversion in humans

Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice

Protective effect of A/H1N1 vaccination in immunemediated disease--a prospectively controlled vaccination study

Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Correlates of protection against SARS-CoV-2 in rhesus macaques

Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

We would like to thank our patients and their families for participating in this study. We are grateful to Luz Alvarado, Rhina Medina, Parvathi Girija, Jyoti Patel and Zakwan Uddin for coordinating and for data entry efforts. We would also like to thank Rebecca Cohen for regulatory support.Contributors RHH and JUS designed the New York study, designed the data collection tools, analysed and cleaned the data, and drafted and revised the paper. RH, MS and MM designed the New York study, designed and performed the cellular analysis, and revised the paper. SA designed the New York Study and revised the paper. RBB designed the New York study, acquired data and revised the draft. DS, RA, KT, MN and GS designed the Erlangen study, designed the data collection tools, analysed and cleaned the data, and revised the paper. SA aided in original design, statistical analysis and revised the paper. MT, SK, RA and AC analysed data and revised the draft. RC, PR, GS, NA, PR, PI, JS, BG and SMR helped accrue data and revised the draft. properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/.

David Simon http:// orcid. org/ 0000-0001-8310-7820 Steven B Abramson http:// orcid. org/ 0000-0002-0668-6344 Georg Schett http:// orcid. org/ 0000-0001-8740-9615 Jose U Scher http:// orcid. org/ 0000-0002-1072-6994

Competing interests JUS declares that he has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, UCB and Abbvie and has received funding for investigatorinitiated studies from Novartis, Sanofi and Janssen. GS has served as a consultant for Abbvie, BMS, Eli Lilly, Gilead, GSK Novartis, Janssen and Roche and has received funding for investigator-initiated studies from BMS, Eli Lilly, GSK, Novartis and UCB. MM declares grants from Eli Lilly, Pfizer and Sanofi and personal fees from Meissa Vaccines. PI has received consulting fees from GSK. RHH has received consulting from Janssen. SA reports grant support from Johnson and Johnson. GS declares consulting fees from AbbVie.

Ethics approval New York University IRB 20-01078, University Clinic of Erlangen IRB 157_20B.Provenance and peer review Not commissioned; externally peer reviewed.Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Further deidentified data can be made available upon request. Jose. scher@ nyulangone. org.Twitter David Simon: @DavidSi62640075Mark J. Mulligan: @mjmull Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is